Purpose Luteolin, a flavone present in many foods and medicinal plants, may have beneficial effects on various human chronic diseases. In the present study, we investigated the hypothesis that luteolin can directly act on vascular endothelial cells (ECs), leading to nitric oxide (NO) production and subsequent vascular relaxation. Methods Rat aortic rings were mounted in organ bath. Luteolin was added cumulatively, and vessel relaxation of rat aortic rings precontracted with phenylephrine (PE) or potassium was recorded. Endothelial nitric oxide synthase (eNOS) phosphorylation at Ser1177 and NO production from aortic rings and primary human aortic endothelial cells (HAECs) exposed to luteolin were measured by using Western blot and fluorometric assay, respectively. Results Luteolin dose-dependently (10-100 lmol/L) elicited relaxation of PE-or potassium-contracted aortic rings. The vasorelaxation effect of luteolin was attenuated by the eNOS inhibitor, N-nitro-L-arginine methyl ester, suggesting that this luteolin action is at least partially mediated by activating eNOS activity. We further found that luteolin dose-dependently (10-100 lmol/L) increased eNOS phosphorylation at Ser1177 (up to 1.9-fold) in isolated rat rings. Consistently, exposure of HAECs to luteolin also increased eNOS phosphorylation and NO production. Conclusions Luteolin may be a vascular protective agent by directly acting on vascular ECs to stimulate NOdependent vascular dilatation.
Introduction
It is known that the classic and specific a (1) adrenergic receptor (a 1 -AR) agonist, phenylephrine (PE), exerts a positive inotropic effect on vascular smooth muscle which is opposed by products of the vascular endothelium. Specifically, within the cardiovascular system, there is a paracrine antagonism through which the product of endothelial nitric oxide synthase (eNOS), nitric oxide (NO), moderates the effects of a 1 -AR-mediated contraction [1, 2] . That is, the endothelial layer of the arterial vasculature increases NO release by increasing eNOS activity during a 1 -AR-mediated sympathetic agonism, thus moderating arterial blood pressure. Disruption of this concerted mechanism between a 1 -AR agonism and eNOS stimulation may have clinically relevant ramifications. Impairment of eNOS stimulation and the subsequent decrease in NO release is thought to contribute substantially to molecular mechanisms associated with essential hypertension [3, 4] . Because of this pivotal role for NO in blood pressure homeostasis, modulation of NO bioavailability is considered a major target for treatment of essential hypertension.
Luteolin is a bioflavonoid present in many food products and medicinal plants including artichoke (Cynara cardunculus), one of the world's most well-known ''medicinal'' plants with a long history of pharmacotherapeutic use [5] [6] [7] . Recent investigations have showed that luteolin or artichoke extracts have numerous beneficial medicinal properties such as anticancer, antioxidant, anti-inflammatory, and anti-allergic actions [8] [9] [10] [11] [12] [13] [14] . The cardioprotective properties of luteolin or artichoke extracts include lowering plasma lipids [15] , inhibiting cholesterol biosynthesis [16] , preventing LDL oxidation [17] , and increasing eNOS gene expression [18] . There are also studies showing that luteolin improves vascular relaxation and prevents age-associated loss of vasomotor function [19] . How luteolin affects vascular relaxation, however, remains controversial. While some studies show that luteolin relaxes smooth muscle independently of NO [20] , other research reports roles for luteolin in both NO-coupled vasodilatation and NO-independent modulation of Ca 2? and K ? channels [21, 22] . The current study was undertaken to further clarify the mechanism of luteolin action in vascular relaxation using rat aortic rings and primary human aortic endothelial cells (HAECs).
Materials and methods

Materials
Primary HAECs and endothelial growth supplements 2 (EGM2) were purchased from Lonza Walkersville (Walkersville, MD, USA); nitrite/nitrate fluorometric assay reagents were purchased from Cayman Chemical (Ann Arbor, MI, USA); antibodies for eNOS and phospho-eNOS were from Cell Signaling Technology (Beverly, MA, USA); nitrocellulose membranes and protein assay kits were from Bio-Rad (Hercules, CA, USA); luteolin, eNOS inhibitor N-nitro-L-arginine methyl ester (L-NAME), PE, and other general chemicals were from Sigma (St. Louis, MO, USA). Stock solutions of luteolin, at 100 mmol/L in dimethyl sulfoxide (DMSO), were stored at -80°C before use.
Rat isolated aortic rings
Male Sprague-Dawley rats (250-300 g) were killed using CO 2 , and the chests were opened immediately to isolate the thoracic aorta. After removal of superficial connective tissues, the aorta was cut into ring segments, 3-4 mm in width, which were then mounted in standard 5-mL organ baths filled with continuously gassed (95 % O 2 :5 % CO 2 ) Krebs-Henseleit (KH) buffer (pH = 7.4) of the following composition in mmol/L; 118 NaCl, 25 NaHCO 3 , 3.7 KCl, 1 KH 2 PO 4 , 11.1 glucose, 1.2 MgSO 4 , and 2.0 CaCl 2 at 37°C. Aortic rings were equilibrated for 90 min at a resting tension of 2 g. Aortic rings were then precontracted with three courses of 80 mmol/L KCl to achieve consistent contraction. After a 30-min washout with KH buffer, all vessels were returned to and stabilize at a resting tension of 2 g. At the conclusion of the experiments, samples were desiccated to dryness at 100°C and results were presented as mg of tension per mg of dry weight. The animal protocol was approved by the Institutional Animal Care and Use Committee at Virginia Polytechnic Institute and State University (Animal Welfare Assurance # A-3208).
Characterization of the vasorelaxant response to luteolin Aortic rings were constricted by the serial addition of PE to determine the concentration of PE required for 0.5 maximal response (EC 50 ), which was found to be approximately 1 lmol/L. Vessels were then tested for endothelial integrity with a single addition of 10 lmol/L acetylcholine (Ach). Only aortic rings that relaxed with Ach challenge were used in the following experiments. After washout and re-equilibration with KH buffer (until all vessels return to and stabilize at a resting tension of 2 g), the aortic rings were contracted with 1 lmol/L PE. When the contractile response stabilized (steady-state phase for 15 min), relaxation was evaluated by cumulative addition of luteolin from 1, 5, 10, 30, and 100 lmol/L. Each concentration was incubated to the steady-state phase for 15 min. Identical concentrations of DMSO alone were added to the control group at the same time interval as the addition of luteolin. In some experiments, cumulative addition of luteolin was made with or without the specific inhibitor of eNOS, L-NAME at 300 lmol/L as described in previous study [23] .
Cell culture Primary HAECs were cultured in M199 medium containing 2 % FBS and EGM2 at 37°C in a 5 % CO 2 /95 % air environment. The medium was changed every other day until the cells became confluent. HAECs were passaged after 0.05 % trypsin treatment, and passages 4-6 were used in all experiments.
Western blot analysis
Equal amounts of protein from HAECs or aortic tissue extracts were subjected to Western blot analysis as we described [24, 25] . Membranes were probed with antibody against phospho-eNOS. The immunoreactive proteins were detected by chemiluminescence. Nitrocellulose membranes were then stripped and re-probed with eNOS antibody. The protein bands were digitally imaged for densitometric quantitation with a software program (Gene Tools, Synoptics Ltd. Cambridge, UK). The expression of phosphoeNOS was normalized to that of eNOS.
NO measurement
To investigate the effect of luteolin on NO release from ECs, confluent HAECs grown in 12-well plates were serum-starved in Hank's balanced salts solution (HBSS; 135 mmol/L NaCl, 1.2 mmol/L CaCl 2 , 1.2 mmol/L MgCl 2 1.2, 5 mmol/L KOH, 10 mmol/L HEPES, 10 mmol/L glucose, pH 7.4) supplemented with L-arginine (0.1 mmol/L) for 30 min, followed by stimulation with various concentrations of luteolin (0, 1, 5, 10 lmol/L) for 30 min. This serum starvation was to prevent the deactivation of the normal enzyme activity by serum proteins, a procedure that is commonly used in the enzyme activity studies [26] . Culture supernatants were then collected for NO assay. NO production was determined by using a fluorometric assay as previously described [27] and normalized to that of protein in the same sample.
Statistical analysis
Data were analyzed with one-way ANOVA using SAS Ò software and are expressed as mean ± standard error (SE) of three or four independent experiments. Treatment differences were subjected to Tukey's multiple comparison tests, where P \ 0.05 was considered significant.
Results
Luteolin dose-dependently relaxes PE-induced contraction in rat aortic rings
To evaluate the potential effect of luteolin, aortic rings were precontracted by PE (1 lmol/L) and, when the contractile response was stabilized (steady-state phase at 15 min), relaxation was evaluated by the addition of luteolin. Our results show that luteolin (10-100 lmol/L) leads to immediate and dose-dependent vasorelaxation in aortic rings (Fig. 1 ).
Luteolin induction of vasodilatation is partially inhibited by eNOS inhibitor in rat aortic rings
After the PE (1 lmol/L)-induced contraction reached maximum, serial additions of luteolin were made with or without the specific inhibitor of eNOS, L-NAME (300 lmol/L) [23] . As shown in Fig. 2 , the effect of luteolin in relaxing PEinduced tension was partly abolished by L-NAME, suggesting that luteolin modulates vascular tension at least partially through the eNOS-/NO-dependent pathway.
Luteolin acutely stimulates eNOS phosphorylation in isolated rat aorta Once PE-induced contraction reached a stable plateau (about 80 % contraction), aortic rings were then exposed to different concentrations of luteolin (1, 5, 10, 30 , and 100 lmol/L) for 30 min. The rings were immediately processed for measuring eNOS activity as determined by Western blot analysis of phosphorylated eNOS. As shown in Fig. 3 , luteolin stimulated phosphorylation of eNOS at Ser 1177, suggesting that the vascular dilatory effect of luteolin in aortic rings is due to the activation of eNOS. We therefore further determined whether luteolin is able to reduce vascular tension caused by KCl. In this regard, aortic rings were constricted with either KCl or PE and then relaxed with increasing concentrations of luteolin. As shown in Fig. 4 , luteolin can relax KCl-contracted vessel rings, but the magnitude of this effect is less than that from PE-contracted aortic rings. This observation suggests that luteolin may also suppress contraction by an ionotropic mechanism, in addition to increasing NO production.
Luteolin stimulates eNOS phosphorylation and NO production in HAECs
To determine whether luteolin can also stimulate eNOS in human ECs, we incubated HAECs with various concentrations of luteolin for 30 min. As shown in Fig. 5 , luteolin dose-dependently activated eNOS phosphorylation at Ser 1177 ( Fig. 5a ) and increased NO release (Fig. 5b) in HAECs. These findings suggest that luteolin activation of eNOS is not species specific.
Discussion
Our current study demonstrates that luteolin induces rapid activation of eNOS both in rat aortic rings and in HAECs, leading to NO production in HAECs and relaxation of PEor KCl-induced contraction in rat aortic vessels. Our observation supports a possible role for the inclusion of luteolin in regimens to combat essential hypertension. Blood pressure is controlled by the tonic constriction and dilation of blood vessels, vasomotion, the degree of Luteolin: µmol/L Fig. 3 Luteolin dose-dependently activates eNOS phosphorylation in rat aorta. Aortic rings were incubated with various concentrations of luteolin for 30 min, followed by determination of the phosphorylated and total eNOS levels as described in ''Materials and Methods'' section. The experiment was repeated three times, and data are expressed as mean ± SE. *P \ 0.05 versus vehicle-treated control 2? via activation of guanylate cyclase and production of cGMP (cyclic guanosine monophosphate) [34, 35] , as illustrated in Fig. 6 .
In the present study, we found that luteolin-induced relaxation cannot be abolished completely by inhibition of eNOS activity, indicating that luteolin may suppress SMC contraction by multiple mechanisms. A comparison of the vasorelaxant effect of luteolin on PE-and KCl-contracted aorta found that the capacity of luteolin to reverse PEinduced contraction was greater than its capacity to block KCl-induced tension. This disparity may reflect the difference by which these two agents elicit vasoconstriction.
Phenylephrine-induced vasoconstriction is initiated by binding to its specific receptor (a 1 -ARs) which then activates phospholipase C, leading to inositol 1,4,5-trisphosphate and diacylglycerol production [36, 37] and subsequent mobilization of intracellular Ca 2? stores. On the other hand, KCl-induced contractions are produced via the opening of voltage-dependent Ca 2? channels [29] . Therefore, the greater efficacy of luteolin to reverse PEcompared with KCl-constricted aortic rings may be attributed to the different mechanisms of contraction. Interestingly, similar disparate results have been observed with other NO-producing agents including acetylcholine chloride, diethylanine NONOate, and glyceryl trinitrate [38] .
Because of the role of NO in preventing and treating essential hypertension, increasing endogenous NO bioavailability is a priority strategy that may help maintain normal vascular tone. In this regard, natural phytochemicals, like flavonoids, are particularly attractive and more than dozen of flavonoids have been tested. An earlier study [39] showed that the order of common flavonoid potency for vascular relaxation has been established as follows: flavones (apigenin and luteolin) [ flavonols (kaempferol and quercetin) [ isoflavones (genistein and daidzein) [ flavanes (catechin and epicatechin). While some of flavonoids, such as genistein [24, 27, 40] and epicatechin [41, 42] , have been shown to activate eNOS and NO production, no study, to our knowledge, has investigated if luteolin can directly stimulate eNOS activity in ECs. Li et al. [18] reported that luteolin and whole extract from Artichoke up-regulates eNOS expression and mRNA transcription in human ECs. The current study demonstrates that luteolin rapidly activates eNOS phosphorylation both in rat aortic rings and in HAECs (Figs. 3, 5) , and most importantly, this eNOS activation and vasorelaxant effect of luteolin (10-100 lM) may be physiologically relevant because plasma concentrations of luteolin after oral intake can reach up to 19.3 lmol/L [43] , suggesting that dietary supplementation of luteolin could be useful both clinically to reduce and practically to prevent hypertension. Although endothelium and eNOS were already damaged in most pathophysiological conditions, the damaged endothelium and eNOS expression/activity can be reversed or partially restored by either naturally occurring or pharmacological vasoactive agents such as genistein [40] and b-lapachone, a well-known substrate of NAD(P)H:quinone oxidoreductase (NQO1), in hypertensive rats [44] , indicating that luteolin could be a potentially useful and low-cost agent for preventing and treating hypertension.
The activation of eNOS can be regulated by several intracellular kinase-mediated signaling pathways such as PI3K/Akt, PKA, or AMP-activated kinase [26] . It is still unclear how luteolin induces rapid eNOS activation in ECs. An earlier study showed that luteolin dose-dependently (10-300 lmol/L) inhibits cAMP-specific phosphodiesterase [20] , thereby allowing cAMP accumulation. We recently demonstrated that activation of the cAMP/PKA cascade leads to increased eNOS phosphorylation and NO production in ECs [27] . Therefore, it is speculated that luteolin may activate eNOS through a cAMP-/PKA-mediated mechanism. We are currently investigating this hypothesis.
In summary, this study demonstrates for the first time, to our knowledge, that luteolin can directly act on vascular ECs, leading to rapid eNOS activation and NO production, thereby causing relaxation of vascular tension in rat aortic rings. Consistently, luteolin also induces eNOS activity and subsequent NO production in primary HAECs. These findings provide a basic mechanism underlying potentially laudatory physiological effects of luteolin in the vasculature. 
